# A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

> **NCT04139304** · EARLY_PHASE1 · RECRUITING · sponsor: **AIDS Malignancy Consortium** · enrollment: 15 (estimated)

## Conditions studied

- Plasmablastic Lymphoma
- Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Doxorubicin
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Etoposide
- **DRUG:** Prednisone
- **DRUG:** Vincristine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT04139304
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2029-07
- **Final completion:** 2030-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04139304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04139304, "A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04139304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*